The use of stem cells in the treatment of traumatic spinal cord injury (SCI) in recent years has provided promising results. Different sources of cells for transplantation have been used, including neural progenitor cells (NPCs), neural stem cells (NSCs) or embryonic stem cells (ESCs). Experimental and clinical studies are currently underway to define the potentials of stem cells in the treatment of SCI. As implantation-based neural cellular restoratory therapy develops, SCI that has not been typically treated by surgical procedures, will be ultimately introduced within the realm of neurosurgery. It is thus imperative that neurosurgeons have an understanding of and in-depth training in research endeavors related to the field of stem cell biology. This paper aims to briefly review the current status and potential of using stem cells to repair experimental SCI.
INTRODUCTION
Traumatic spinal cord injury (SCI) often results in significant neurologic dysfunction and disability. The annual incidence of SCI in developed countries varies from 11.5 to 53.4 per million population (23, 46) . Much research over the past 30 to 40 years has focused on elucidating the mechanisms underlying the complex pathophysiologic processes being slowly unraveled following SCI. It is now generally accepted that acute SCI is a two-step processes involving primary and secondary events (3, 14, 51) . The primary process involves the initial mechanical injury due to local deformation and energy transformation, whereas the secondary mechanism encompasses a cascade of biochemical and cellular processes that are initiated by the primary process and may cause ongoing cellular damage, cell death, axonal loss and demyelination (3, 46, 51) . These pathophysiological features plus the dearth of available treatment options for SCI have made the injured spinal cord an attractive target for studying cell-based therapies (5, 16, 33, 41) . Importantly, it has been increasingly appreciated that with effective neuroprotection in place provided by donor cells including neural stem cells (NSCs), other treatments aiming to promote axonal regrowth and neural plasticity, if started simultaneously or immediately thereafter, may synergistically enhance functional restoration (5) . In pursuing this possibility, experimental use of neurotrophins or neurotrophic factors to increase neuroprotection and axonal growth, neutralizing antibodies to Nogo and other oligodendrocyte-related inhibitory molecules and drugs to increase intracellular levels of cAMP have been investigated (2, 4, 5, 35, 45, 56) . Furthermore, several studies have suggested that NSCs, when transplanted into the injured brain or spinal cord of rodents, migrate preferentially to and become integrated within the damaged areas. A subpopulation of the transplanted NSC is redirected to differentiate into cell types that might replace the diseased or degenerated host cells (36, 37, 43, 60) . Thus, the initial primary rationale was that cell-based strategies for reconstituting the injured spinal cord must accommodate the need to replace multiple cell types (13, 16, 49) .
Definition of Stem Cells
Stem cells are defined as immature, uncommitted cells that are able to self-replicate in tissue culture, (15) .
Potential for Using NSCs to Repair the Injured Spinal Cord
SCI is associated with the loss of both neurons and glia (13, 55) . Improved functional outcomes after SCI may be elicited by neuroprotective approaches that limit secondary tissue loss and thus the loss of function. Alternatively, functional recovery could be elicited by axon growth and neural plasticitypromoting approaches that result in restoration of damaged and/or formation of new neural circuits that could become involved in functional recovery (22, 55) . There is little doubt that stem cells and neural progenitor cells could become invaluable components of repair strategies for the spinal cord. NSCs, by definition, can become neural cells that may support anatomical/functional recovery. Alternatively, they may secrete growth factors that could support neuroprotection and/or neurite reorganization. The potential of stem cells or progenitor cells to mediate spinal cord repair has been studied extensively (10, 17, 55, 59) . The potential problems related to stem cell application to neural repair have also been discussed (9, 57, 59, 63) . For instance, over the last decade, stem cells have often been studied without implementing explicit bench criteria that would define the used cells as such. These and other matters regarding the use of stem/progenitor cells for SCI treatment also need to be resolved before effective therapies can be developed (63) .
Clinical Potential of NSCs
Various treatment strategies have shown benefit in experimental animal models, there is still no effective therapy for clinical SCI. This difficult situation, in our opinion, is attributable to the following realities. First, there has been no conclusive evidence favoring one process as the predominant pathophysiological mechanism which can account for all the spinal dysfunction seen following SCI. Most of the pathophysiological processes (e.g., secondary molecular events: glutamate toxicity, sodium and calcium influx, free radical insult, cytochrome c release; secondary pathophysiological events: ischemia, anoxia, apoptosis, etc.) apparently exist either simultaneously or sequentially in an interlocked or independent manner throughout the evolution of the injury and represent different facets of this complicated disease entity (3, 51, 52) . Most interventions reported to date target solely one facet of the injury process which, in isolation, is doomed to have limited benefit. To further complicate the situation, a given approach that may be useful when used alone, may become ineffective or even detrimental when used in combination with other interventions, perhaps working at cross purposes. Hence, it is critical to understand the intricate interactions between these options and identify the underlying mechanisms of their actions so that they may be orchestrated in a safe, synergetic, and clinically feasible fashion (5, 41) . Given these challenges, the use of a "therapeutic anchoring vehicle" such as the NSC has been deemed to be an appealing strategy to address multiple pathological processes simultaneously while effecting functional recovery (55, 56, 57) . In an ideal situation, the "therapeutic anchoring agent" should be (a) multipotent in terms of assuming the roles of different neural cell lineages and performing different functions, including functions at play early (50) . They therefore suggested that NSC transplantations should be performed during the subacute stage after injury to achieve maximum therapeutic potential, which additionally indicates that there may be a practical therapeutic window for applying NSC to treat SCI clinically (50) .
Comprehensive Impact of NSC on the Injured Spinal Cord
To date, as a therapeutic tool in the treatment of neurologic disorders, the most promising results have been obtained using hNSC isolated directly from the human fetal neuroectoderm. The propagation ability of such tissue-derived hNSC is sometimes limited, making it difficult to establish a large-scale culture. Following engraftment, these hNSC often show low efficiency in generating the desired neuronal cells necessary for reconstruction of the damaged host milieu and, as a result, have failed to give satisfactory results in clinical trials so far. Alternatively, human embryonic stem cells (hESC) or induced ploripotent stem (iPS) cells offer a pluripotent reservoir for in vitro derivation of a rich spectrum of well-characterized neural-lineage committed stem/progenitor/precursor cells that can, theoretically, be picked at precisely their safest and most efficacious state of plasticity to meet a given clinical challenge (38) . Considering the ability of stem cells to become any cell types they are related developmentally, their potential use for cell replacement is a common sense-derived strategy (59) , for this purpose, ESCs or iPS cells are indeed likely sources for cell replacement treatment of SCI. On the other hand, one of the main problems of ES or iPS cell-based cell therapy is tumor formation, to date there is no an ideal method to suppress tumor development from ESCs/iPSCs (29) . Conversely, with the appropriate combination of (growth) factors (induction cocktail), ESCs can be used to (34, 59) . Moreover, these cells are able to myelinate axons after transplantation into the spinal cord of myelindeficient shiverer mice and adult rats (21, 59) .
NSC implants into the injured spinal cord have been used under the initial premise that regionally appropriate phenotypes might be generated from undifferentiated cells in response to local signals competent to induce cell type-specification (16) . However, more intriguingly -ultimately, of greater importance and utility -is the observation that undifferentiated NSC or NSC that have pursued a glial lineage seem to recondition the host CNS microenvironment and promote functional recovery by protecting pre-existent but threatened host neurons and circuitry (54). The impact of this action is probably greater than neuronal replacement. The precise mechanism by which NSC exert this homeostatic pressure is unclear, though it is likely attributable to a large degree by intrinsic ability of NSC to secrete neurotrophic factors, and/or immunomodulators, and form gap junctions with host cells (18, 28, 39, 40, 54, 56) . Thus, preserving the multipotency of these cells -as opposed to attempting to direct them invariantly down the differentiation pathway of a single cell type -might offer the greatest chance for cell-based therapies of the different inter-locked stages of SCI but in a parsimonious fashion. Harnessing the potentially broad therapeutic capacity of the NSC for use in an intelligent and rationale manner requires learning the principles that can govern interaction between the pathologic target and host environmental components, the NSC, and other therapeutic reagents.
The innate biology of NSC (i.e., their default production and secretion of various neurotrophic factors and other molecules in a differentiation stage-dependent fashion) enables them to interact with the surrounding environment, including releasing trophic factors in an appropriate, regulated, stimulusappropriate manner. These factors, in our view, are components of the stem cell's inherent developmental program which "calls upon it" to exert homeostatic forces upon a dynamically growing nervous system which, otherwise, could become dysequilibrated. The result of this inherent "program" -a dividend from developmental biology -is to promote, enable, induce, or catalyze the host to attempt to reconstitute its own tissue, to minimize barriers to this process, and to protect endangered cells from cell death or other toxic influences (53) .
Regarding endogenous NSC and their possible roles in SCI repair, these cells have been found to reside in a few well-characterized secondary germinal zones of the adult central nervous system, most notably the subgranular zone (SGZ) of the dentate gyrus of the hippocampus and the subventricular zone (SVZ) along the anterior part of the lateral ventricle in the forebrain. Endogenous NSC may also reside in the ependymal region of the spinal cord. In response to injuries like stroke, adult hippocampal NSC may proliferate and differentiate into new, functioning neurons (44) . However, NSC in the adult spinal ependymal region do not seem to differentiate into neurons when they reside in their normal spinal cord niche. Nevertheless, when these same NSC are transplanted into the SGZ, they do yield neurons (12, 19, 47) . Hence, limitations to neurogenesis must emanate in large part from the microenvironment of the adult spinal cord rather than from the cells themselves. Therefore, it seems feasible that either altering the milieu or changing the cells to respond differently to that milieu may permit these endogenous spinal NSC to play a more prominent role in neuronal reconstitution in the adult cord (11, 55) . To overcome the normal impediments to adult neurogenesis will require a better understanding of the biological roles of spinal NSC, especially their proliferation in response to injury, inflammation, and rehabilitation-mediated neuroactivity -all significantly unexplored (55 (30) . Although this recovery was at first attributed to the few neurons that appeared to emerge, a more detailed study showed that functional impact may, in fact, have been more plausibly due to oligodendrocyte that myelinated some traumatized host axons (27) . Since the injured cord offers a microenvironment that appears not favorable to the differentiation of multipotent NSC into neurons (7), it has been proposed that transplanting neuronal and glial restricted precursors (NRP/GRP: i.e., pre-committing the cells to a particular lineage ex vivo rather than letting the in vivo environment direct their differentiation) may be a more practical approach.
The transplantation of NRP/ GRP into the postcontusion spinal cord did improve motor and sensory function. Histological analysis showed that a subset of the NRP/GRP survived, filled the lesion site, differentiated into neurons and glia, and migrated selectively (6, 31) . Interestingly, the volume of spinal cord spared was increased in NRP/ GRP recipients, suggesting that their action may nevertheless have been attributable in a large part to local neuroprotection. The actual role that donorderived neurons played in recreating neurocircuitry is presently not determined. Kumagai and colleagues showed that transplantation of the gliogenic secondary neurospheres (SNS), but not the neurogenic primary neurospheres (PNS), promoted axonal growth, remyelination, and angiogenesis, and resulted in significant locomotor functional recovery after subacute SCI rodent model. Their finding suggests that gliogenic neural stem/progenitor cells (NS/PCs) may be also effective for promoting the recovery from SCI, and may provide an additional tool to investigate the mechanisms through which cellular transplantation leads to functional improvement after SCI (13, 24) . Thus, further investigation is necessary to precisely define the cell biology, safety, and potential therapeutic benefits of transplanted stem cells that are predifferentiated into neural cells prior to their introduction into formal clinical trials.
Future Directions of Functional Restoration for SCI
As data elucidating the complexity of spinal cord injury pathophysiology emerge, it is increasingly being recognized that successful repair will probably require a multifaceted approach that combines tactics from various biomedical disciplines, including cell transplantation, gene therapy, material sciences and pharmacology. Recently, new evidence highlighting the benefit of physical activity and rehabilitation interventions during the postinjury phase has provided novel possibilities in realizing additional efficacy of NSC-mediated repair after spinal cord injury. However, we believe that the basic mechanisms by which these various interventions act must be thoroughly explored and important synergistic and antagonistic interactions identified, before a comprehensive therapeutic strategy that optimally utilizes the benefits of each of these disciplines can be designed. In examining the mechanisms by which physical activity-based functional recovery after spinal cord injury is affected, endogenous neural stem cells, in our opinion, engender a potentially key role that theoretically can be mimicked or further augmented by transplantation of human NSC or other types of progenitor cells (32) . In terms of applying chemical engineering strategies to additionally enhance the therapeutic potential of stem cells, the use of scaffolds and cellular bridges are well-suited for lesions in which there is large parenchymal loss or where a syrinx might otherwise form because of extensive cell death following contusion (54, 61). Recently, others and we have shown that the ability of fibrin scaffolds or drug-embedding PLGA to exert the controlled release of growth factors or free radical scavengers to enhance the survival/ differentiation of neural progenitor cells and impede secondary injury, respectively, following transplantation into a SCI model (20) .
In summary, the experimental data, overall, advocates the incorporation of stem cell implantation or activation of endogenous NSCs as a component of the multidimensional treatment of spinal cord injury and underscores the critical need to employ research-based mechanistic approaches for developing future advances in the stem cell therapies for neurological injury and disorders. 
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